Caligan Partners LP: XENON PHARMACEUTICALS INC (XENE): Quarterly 13F Position History
As of Q1 2026, Caligan Partners LP reported 1,393,027 shares of XENON PHARMACEUTICALS INC (XENE), worth $81.0M and representing 5.7% of its 13F equity book. Quarter-over-quarter share count change: + 843,362 (+153.4%) . The position first appeared in Q3 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.
- 1,393,027Shares Held (Latest Filing)
- $81.0MReported Market Value (Latest Filing)
- 5.7%Portfolio Weight (% of 13F Equity Book)
- +843,362Quarter-over-Quarter Share Change
- +$56.4MQuarter-over-Quarter Value Change
- 1,393,027Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,393,027 | +843,362 | +153.4% | $81.0M | 5.7% | $58.1 |
| Q4 2025 | 549,665 | +105,100 | +23.6% | $24.6M | 2.3% | $44.8 |
| Q3 2025 | 444,565 | — | — | $17.8M | 2.5% | $40.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Caligan Partners LP first disclose a XENE position in 13F-HR filings?
Caligan Partners LP first reported XENON PHARMACEUTICALS INC (XENE) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.
What was Caligan Partners LP's most recent quarter-over-quarter share-count change in XENE?
Between Q4 2025 and Q1 2026, Caligan Partners LP added 843,362 shares of XENE (+153.4%), bringing the total reported position to 1,393,027 shares at a market value of $81.0M.
Does the implied price-per-share represent Caligan Partners LP's cost basis in XENE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.